RANI
NASDAQRani Therapeutics Holdings Inc.
Price$0.84+0.02 (+1.88%)
01:30 PM02:45 PM
News · 26 weeks43+233%
2026-02-082026-08-02
Mix3090d
- Insider15(50%)
- SEC Filings6(20%)
- Other5(17%)
- Offering2(7%)
- Leadership2(7%)
Latest news
25 items- SECSEC Form 8-K filed by Rani Therapeutics Holdings Inc.8-K - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- PRRani Therapeutics Appoints Michelle Gilson to Board of DirectorsSAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced the appointment of Michelle Gilson to its Board of Directors. Ms. Gilson will serve as Chair of the Audit Committee. "The combination of deep capital markets expertise and hands-on financial leadership at a high-growth biotechnology company makes Michelle an exceptional addition to our Board," said Talat Imran, Chief Executive Officer of Rani Therapeutics. "Her experience guiding Arcellx through its partnership and acquisition by Gilead gives her a firsthand understanding of how disciplined finan
- INSIDERDirector Imran Mir A bought $24,840 worth of shares (36,000 units at $0.69), increasing direct ownership by 2% to 2,119,334 units (SEC Form 4)4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERChief Technical Officer Javadi Alireza sold $301 worth of shares (386 units at $0.78) and covered exercise/tax liability with 309 shares, decreasing direct ownership by 7% to 9,380 units (SEC Form 4) (withholding obligation)4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERChief Executive Officer Imran Talat bought $25,193 worth of shares (35,000 units at $0.72), increasing direct ownership by 8% to 469,736 units (SEC Form 4)4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERChief Executive Officer Imran Talat sold $11,300 worth of shares (8,014 units at $1.41) and covered exercise/tax liability with 52,001 shares, decreasing direct ownership by 12% to 434,736 units (SEC Form 4) (withholding obligation)4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Maestas Nicholas4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- PRRani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics"; "Rani" or the "Company") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani’s new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani. The stock option was granted on July 17, 2026. The stock option has an exercise price of $0.6973 per share, which is equal to the closing price of Rani’s Class A common stock on the grant date, h
- SECSEC Form S-8 filed by Rani Therapeutics Holdings Inc.S-8 - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- PRRani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous DosingRT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeuticsPhase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity SAN JOSE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today reported positive initial data from the ongoing Phase
- PRRani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~ ~ Agreement expands Rani's obesity franchise beyond its existing programs, potentially adding multiple new candidates across differentiated mechanisms of action ~ SAN JOSE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced a research and development collaboration with PegBio Co., Ltd. ("PegBio") to explore the delivery of multiple novel candidates f
- INSIDERSEC Form 3 filed by new insider Maestas Nicholas3 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- PRRani Therapeutics Appoints Nicholas Maestas as Chief Financial OfficerSAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics"; "Rani" or the "Company") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Nicholas Maestas as Chief Financial Officer, effective immediately. "We are pleased to welcome Nicholas as our new Chief Financial Officer," said Talat Imran, Chief Executive Officer of Rani. "His depth of experience in biopharma capital markets and corporate strategy makes him well-suited to steward Rani through its next chapter. We also want to again thank Svai Sanford for his steady leadership over the years and hi
- INSIDERSEC Form 4 filed by Chief Business Officer Mckinley Kate4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Chief Technical Officer Javadi Alireza4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Imran Talat4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Director Bassan Abraham4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Director Rometty Lisa Ann4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Director Imran Mir A4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Director Butel Jean Luc4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Director Bailey Vasudev Jaiprakash4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Director Ausiello Dennis A4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Rani Therapeutics Holdings Inc.SCHEDULE 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
- SECSEC Form 8-K filed by Rani Therapeutics Holdings Inc.8-K - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- SECSEC Form 424B5 filed by Rani Therapeutics Holdings Inc.424B5 - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
RANI FAQ
7 questionsWhat does Rani Therapeutics Holdings Inc. do?
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a...Where does RANI stock trade?
Rani Therapeutics Holdings Inc. (RANI) is listed on NASDAQ.What sector and industry is RANI in?
Rani Therapeutics Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Rani Therapeutics Holdings Inc. go public?
Rani Therapeutics Holdings Inc. (RANI) completed its IPO in 2021.What are analysts saying about RANI?
Rani Therapeutics Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $900.00 price target on 2026-04-14. Recent price targets range from $900.00 to $2800.00.What companies are similar to RANI?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RANI side-by-side with any of them on Quantisnow.How can I track RANI on Quantisnow?
Quantisnow aggregates Rani Therapeutics Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RANI to receive live email and push alerts on every new disclosure.